GlaxoSmithKline: An agreement was reached with the US government to lower drug prices and make respiratory medicine more accessible to millions of Americans. The drugs covered by this agreement are used to treat more than 40 million patients with respiratory diseases such as asthma and chronic obstructive pulmonary disease in the US. GlaxoSmithKline will reserve salbutamol for the US to further guarantee the stability of America's key drug supply chain. The agreement clarifies the future US pricing framework for the two companies, while exempting GlaxoSmithKline and Vivi Pharmaceuticals from Section 232 tariffs for the next three years. Most of its inhaled respiratory drugs and other products will be listed on the US Direct Purchase Platform, and patients can enjoy up to 66% off drug purchases. The specific terms of the agreement with the US remain confidential.

GlaxoSmithKline: An agreement was reached with the US government to lower drug prices and make respiratory medicine more accessible to millions of Americans. The drugs covered by this agreement are used to treat more than 40 million patients with respiratory diseases such as asthma and chronic obstructive pulmonary disease in the US. GlaxoSmithKline will reserve salbutamol for the US to further guarantee the stability of America's key drug supply chain. The agreement clarifies the future US pricing framework for the two companies, while exempting GlaxoSmithKline and Vivi Pharmaceuticals from Section 232 tariffs for the next three years. Most of its inhaled respiratory drugs and other products will be listed on the US Direct Purchase Platform, and patients can enjoy up to 66% off drug purchases. The specific terms of the agreement with the US remain confidential.